3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Thetis Pharmaceuticals is a company with 3 orphan drug designations across 3 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| classic familial adenomatous polyposis | magnesium lysinate bis eicosapentaenoate | Des.TrialAppr. |
| inflammatory bowel disease 1 | Magnesium lysinate bis Resolvin E1 | Des.TrialAppr. |
| malignant pancreatic neoplasm | magnesium lysinate-bis-resolvin E1 | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio